Immunochemotherapy, Surgery or Chemoradiation, and Durvalumab for Stage IIIA/B NSCLC

The hypothesis of the study is that induction immunochemotherapy, followed by surgery or chemoradiation and consolidation Durvalumab immunotherapy, can significantly improve event-free survival in patients with resectable or borderline resectable NSCLC at stage IIIA/B compared to existing treatment methods.

Trial Details

NCT ID
NCT06810609
Phase
PHASE2
Sponsor
University Hospital, Bonn
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • surgery (any volume) and / or pharmaceuticals treatment initiated or planned or only dynamic observation, in accordance with current clinical guidelines
  • Chemoradiotherapy
  • Immunotherapy
Locations (sample)
  • Freiburg im Breisgau, Baden-Wurttemberg, Germany|47.9959,7.85222
  • Stuttgart, Baden-Wurttemberg, Germany|48.78232,9.17702
  • Giessen, Hesse, Germany|50.58727,8.67554
  • Minden, North Rhine-Westphalia, Germany|52.28953,8.91455
  • Bonn, Germany|50.73438,7.09549

Key Eligibility Criteria

  • 1\. Patient is capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed co…
  • 2\. Patient is willing and able to comply with the protocol for the duration of the study 3. Age ≥ 18 years and \< 75 years. 4. All sex and gender.…
  • 6\. Evidence of post-menopausal status or negative serum pregnancy test for female pre-menopausal patients. Women will be considered post-menopausa…
  • 7\. Histologically and / or cytologically proven NSCLC (EGFRm-, ALK-). 8.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →